Petvivo Holdings Inc's Business Segments
Petvivo Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Revenue Share by Reportable Segment - FY
- Sales to Clipper100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Sales to Clipper | $ 0 | 100% |
Revenue by Product & Service Category - FY
- Sales to Vedco69.6%
- Clipper12.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Sales to Vedco | $ 0 | 69.6% |
| Clipper | $ 0 | 12.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Sales to Clipper100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Sales to Clipper | $ 0 | 100% |
Description of Petvivo Holdings Inc
We are based in suburban Minneapolis, Minnesota. We are a biomedical device company, which has been primarily engaged in the business of adapting human biomedical technology for products to be introduced for commercial sale in the veterinary market to treat pets and other animals suffering from arthritis and other afflictions. Our initial product, now being commercialized, is a medical device featuring injections of patented gel-like biomaterials into the afflicted body parts of pets or other animals suffering from osteoarthritis. The technology and manufacturing capability of this product was developed by Gel-Del and acquired by us for use to treat dogs, horses and other animals, but not for treatment of human afflictions. While working together pursuant to our initial license agreement, we and Gel-Del determined to combine our two companies through a stock exchange merger for the purpose of creating one combined entity utilizing Gel-Del technology to produce, market, and sell medical products based on Gel-Del technology for both animals and humans. After lengthy negotiations the parties entered into a definitive agreement for this merger, which resulted in the consummation of the merger in April, 2017.
Segments
1. Veterinary Medicine:
- Petvivo is focused on applying advanced biomaterials in the treatment of various veterinary conditions, particularly orthopedic issues like osteoarthritis and joint injuries in animals.
2. Biomaterials Development:
- Through Gel-Del, Petvivo explores the potential of protein-based biomaterials and devices that replicate the bodys tissues. This segment emphasizes long-term implantation and therapeutic efficacy for both animals and potential future applications in human medicine.
3. Medical Device Manufacturing:
- The company is involved in utilizing proprietary materials for the development of medical devices intended for veterinary and potential human applications, showcasing an integrated approach to biomaterial research and production.
Products and Technologies
Petvivos portfolio includes a range of advanced products designed to enhance the therapeutic options available for treating animal health conditions, particularly in orthopedics:
1. Orthopedic Products:
- KuuR™: A proprietary veterinary device designed to treat osteoarthritis in companion animals. Utilizing a unique formulation, KuuR™ offers pain relief and improved mobility by enhancing joint function.
- OrthoGelic™ and OrthoMetic™: These products are focused on difficult-to-heal bone fractures and orthopedic issues. They employ a biomaterial designed to mimic bone structure, promoting healing and integration while preventing non-bone tissue infiltration.
2. Dermal Technologies:
- While primarily focused on veterinary applications, the biomaterials developed are also applicable for human dermal filler purposes, such as the CosmetaLife®. This technology offers wrinkle reduction through injectable gel particles that rejuvenate dermal tissue.
3. Cardiovascular Products:
- The blood-compatible biomaterial developed by Gel-Del includes the VasoGraft™, a vascular graft designed to facilitate cardiovascular repair. This product embodies qualities that mitigate clotting and promote blood compatibility.
4. Drug Delivery Systems:
- Petvivo also explores drug delivery technologies. Their fabrication techniques allow for the precise distribution of therapeutics via coatings and implantable devices, which could include products such as OraPatch™ for transmucosal delivery, enhancing drug absorption.
Services
1. Research and Development:
- Petvivo emphasizes R&D in both the veterinary and medical device sectors. The company continually seeks to innovate and refine its offerings through research, clinical trials, and partnerships, particularly with Gel-Del, which specializes in developing and manufacturing biomaterials.
2. Regulatory Support:
- The company also has expertise in navigating the regulatory pathways necessary for the approval of veterinary and medical devices, ensuring compliance with veterinary health standards and potentially human medical regulations in the future.
3. Partnership and Collaboration:
- Through agreements and collaborations, particularly with Gel-Del Technologies, Petvivo aims to expand its technological capabilities and market reach in both animal health and broader medical applications.
Conclusion
Petvivo Holdings Inc. represents a dynamic intersection of veterinary medicine and advanced biomaterials technology. With its proprietary products aimed at alleviating orthopedic conditions in animals, and ongoing collaboration with Gel-Del, Petvivo is positioned to lead in innovative treatment solutions within the veterinary sector. Through its range of products and dedicated services, the company is committed to improving animal health outcomes while exploring future applications in the medical technology space.
